![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Safety, Tolerability, Pharmacokinetics (PK) and Antiviral Activity of EDP-494, a Potent Pan-Genotypic Cyclophilin (Cyp) Inhibitor for Chronic Hepatitis C Infection (CHC), in Healthy Subjects (HS) and in CHC Genotype 1 and 3 Patients: Preliminary Results
|
|
|
Reported by Jules Levin
AASLD 2016 Nov 11-15 Boston, MA
Edward J. Gane2,1, Lijuan Jiang3, Christian Schwabe2, Lisa Morelli3, Kai Lin3, Yat Sun Or3, Nathalie Adda3
1New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand; 2Clinical Research Unit, Auckland Clinical Studies,, Auckland, New Zealand; 3Enanta Pharmaceuticals, Inc., Watertown, MA
![HBV1](../images/112816/112816-1/HBV1.gif)
![HBV2](../images/112816/112816-1/HBV2.gif)
![HBV3](../images/112816/112816-1/HBV3.gif)
![HBV4](../images/112816/112816-1/HBV4.gif)
![HBV5](../images/112816/112816-1/HBV5.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|